FDA to fast-track review of BMS' CAR-T, ahead of shareholder...

Speculators who bought into a risky three-drug bet are still on track for a payout following Celgene's merger with Bristol-Myers Squibb, after the FDA agreed to fast-track its review of a n

MorphoSys gets $750m from Incyte for anti-CD19 cancer drug

Scotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphoma

Janssen to develop Darzalex successor with Genmab

Janssen has signed a licence and option deal with Denmark’s Genmab to develop a next-generation drug that it hopes will outperform its already-marketed Darzalex in multiple myeloma, and oth

FDA approves Roche's $90,000 lymphoma combination

The FDA has quickly approved a new antibody treatment for an aggressive form of lymphoma from Roche – costing in the region of $90,000 for a four-month course.

Morphosys to take on CAR-Ts in NHL with promising antibody

Germany’s Morphosys has announced results from its combination therapy of an experimental antibody and Celgene’s Revlimid in a common form of non-Hodgkin lymphoma, saying that the phase 2 t